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Prodigiosin and cycloprodigiosin are tripyrrole red pigmented compounds with medical importance for their
anticancer property. In the present investigation, molecular docking studies were performed for both prodigiosin
and cycloprodigiosins to evaluate the in- silico anti-inflammatory activity against Cycloxigenase-2 (COX-2) protein as
model compound and the data compared with rofecoxib and celcoxid. Cycloprodigiosin showed higher initial
potential, initial RMS gradient and potential energy values compared to prodigiosin. Analysis of COX-2 protein
and ligand binding revealed that cyclprodigiosin interacted with COX-2 protein amino acid residues of Tyr324,
Phe487 and Arg89 while prodigiosin interaction was observed with two amino acids i.e. Leu321 and Tyr324. The
computational ligand binding interaction suggested > 45% higher fitness score value for prodigiosin to that of
cycloprodigiosin with COX-2 protein while the standard compounds rofecoxib and celecoxid revealed fitness score
of 44 and 62, respectively. The prodigiosin ligand revealed the best fitness score compared with the standard drug
rofecoxib suggesting the prodigiosin could be effective as the potential inhibitor compound against COX-2 protein
and can be evaluated as anti-inflammatory drug molecule using clinical trials.
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Inflammation is the tissue reaction against infection, irri-
tation or foreign substance. It is a part of the host
defense mechanisms that is known to be involved in the
inflammatory reactions associated with the release of
histamine, bradykinin & prostaglandins. Clinically in-
flammation, reported by Cornelius Celsus of Rome 2000
years ago, is rubor (redness) or calor (heat) and /or dolar
(pain) at the affected region (Chaudhary 2001) because
of a complex biological response of vascular tissues to
harmful stimuli including pathogens, irritants or dam-
aged cells (Denko 1992).
Cyclooxygenases (COX) or prostaglandin endoperox-
ide synthases (PGHS) are the key enzymes in the
synthesis of prostaglandins, the main mediators of* Correspondence: prakashamr@gmail.com
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in any medium, provided the original work is pinflammation, pain and increased body temperature
(hyperpyrexia). The body produces two main isoforms
COX proteins i.e., cyclooxygenases −1 (COX-1) and
cyclooxygenases-2 (COX-2). The COX-1 is responsible
for formation of important biological mediators such as
prostanoids, including prostaglandins, prostacyclin and
thromboxane and involved in pain causing, blood clot-
ting and protecting the stomach (Watson et al. 2000)
whereas COX-2 involved in the pain by inflammation
and plays a major role in prostaglandin biosynthesis in
inflammatory cells and central nervous system (Chhajed
et al. 2010). When COX-1 is inhibited, inflammation is
reduced, but the protection of the lining of the stom-
ach is also lost. This can cause stomach upset as well
as ulceration and bleeding from the stomach and
even the intestines. Whereas, COX-2 is usually spe-
cific to inflamed tissue, there is much less gastric irri-
tation associated with COX-2 inhibition together with
the decreased risk of peptic ulceration (McGettigan &an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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such as celecoxib and rofecoxib had been developed for
ease of inflammation associated with COX (Hawkey 1999).
The use of coxib drugs such as rofecoxib (VioxxW)
and valdecoxib (BextraW) were withdrawn from the
market in 2004 and 2005, respectively, because of in-
creased risk of heart attacks and strokes with long
term use (Mason et al. 2006). On the other hand,
some studies have suggested that rofecoxib’s adverse
cardiac events may not be a class effect but rather
an intrinsic chemical property related to its metabolism
(Hinz & Brune 2002). At present, Celecoxib (CelebrexW)
is the only COX-2 inhibitor available in the United
States. Hence, there is a need for COX-2 inhibitor with
no adverse effects.
The development of non-steroidal drugs for inflam-
mation especially in overcoming Rheumatoid arthritis
has evoked much interest in the extensive search for
new drugs with anti-inflamatory property (Dandiya &
Kulkarni 1995). Prodigiosins, red pigment compounds
produced by certain gram positive bacterial strains,
gained pharmaceutical and human health care sector
importance mainly due to their selective diverse bio-
logical activities mainly in inhibition of tumor derived
cell lines proliferation with no apparent toxicity towards
normal cells (Yamamoto et al. 1999; Liu et al. 2005)
reported that the tumor cell proliferation inhibition is asso-
ciated with the induction of apoptosis independent of p53
(Castillo-Avila et al. 2005) by suppressing the growth of
tumor originated from chronic lymphocytic leukemia
(Campàs et al. 2003) at metastasis (Zhang et al. 2005).
However, prodigiosins role in anti-inflammatory func-
tion is rarely reported. In the present investigation ef-
forts have been made to evaluate prodigiosin and
cycloprodigiosins, a secondary metabolite alkaloid with a
unique tripyrrole chemical structure produced by a few
species such as Serratia, Pseudomonas and Streptomycin
(Song et al. 2006; Giri et al. 2004) anti-inflammatory
function associated with COX-2 based on docking ana-
lysis as anti-inflammatory agent. This approach is
adopted as evaluation of biological function of any com-
pound especially associated with human trials which is a
long term process and always risky. In this context, mo-
lecular docking continues to hold great promise in the
field of computer based drug design, which screens small
molecules by orienting and scoring them in the binding
site of a protein as a result, novel ligands for receptors
of known structure were designed and their interaction
energies were calculated using the scoring functions. In
view of the above, the present investigation merits in
understanding the imperative role of prodigiosin and
cycloprodigiosin anti-inflammatory properties against
COX-2 protein based on fitness score, type of binding
pattern, energy values etc.Materials and methods
Protein preperation
The X-ray crystallographic structure of COX-2 (PDB ID
1cx2) protein was obtained from the Protein Data Bank
at a resolution of 3.0Å. Water molecules, ligands and
other hetero atoms were removed from the protein mol-
ecule along with the chain B, C and D. Addition of
hydrogen atoms to the protein was performed using
CHARMm force field. Energy minimization was
performed by using conjugate gradient method with an
RMS gradient of 0.01kcal/Å mol on Accelyrs Discovery
studio client (version 2.5) software.
Ligand preperation
The ligand molecules (prodigiosin, cycloprodigiosin,
celecoxib and rofecoxib) structure were drawn in
Hyperchem molecular modeling and visualization tool
(version 7.5) and the energy was minimized using
Accelyrs Discovery studio client (version 2.5) software.
The minimized protein and ligands were saved in PDB
and mol-2 format, respectively for further analysis as
shown in the Figure 1 and the energy values obtained
were shown in Table 1.
Docking using GOLD
Docking simulations were performed using GOLD ver-
sion 4.1.2 for the present study for predicting the pro-
tein–ligand interactions according to Selvaraj (Selvaraj &
Malik 2008). GOLD uses genetic algorithm for docking
and performs automated docking with fully cyclic ligand
flexibility, partial cyclic ligand flexibility and partial flexi-
bility in the neighborhood of the protein active site
(Spassov et al. 2008). The docking process involves a
conformational search for compound which compli-
ments a target binding site, with the aim of identifying
the best matching pose (Chitra & Jeyanthi 2011) along
with the active site to perform docking. The stability of
docked ligand-protein complex is due to hydrogen
bonding and Vanderwaals interactions.
The energy minimized protein and ligand along with
the binding site atom number or the X, Y and Z points
of the Nitrogen atom of the any of the binding site resi-
due submitted to the GOLD setup. All the atoms within
10 Å of the given binding residue atom number were se-
lected for binding pocket. The default parameters of the
automatic settings were used to set the genetic algorithm
parameters. The docked conformation which had the
highest Gold Score was selected to analyze the mode of
binding.
The gold score (fitness), energy, bond and vanderwaals
energies are visualized in gold report which is used for
further analysis. The gold score is a molecular mechan-
ics like function with four terms S(hb_ext), S(vdw_ext),
S(hb_int) and S(int).
Figure 1 3D structure of energy minimized ligand molecules.
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In the present investigation, to screen out potential of
anti-inflammatory properties of the selected tripyrrole
compounds (prodigiosin and cycloprodigiosin) were evalu-
ated through GOLD 4.1 molecular docking studies by
using in silico analysis. Initially, the 3D ligands of these
molecules were generated (Figure 1) followed by energy
minimization. The obtained energy minimization values of
selected prodigiosin and cycloprodigiosin were reported in
Table 1. It was noticed that cycloprodigiosin has higher
initial potential, initial RMS gradient and potential energy
values compared to prodigiosin (Table 1). The variation in
these energy values observed to be different which is ap-
parent due to the structural difference between these nat-
ural pigments of same class. This can be exemplified from
the fact that initial potential energy value for cyclo-
prodigiosin was approximately three-fold while initial
RMS gradient and potential energy values were more or
less two-fold to that of prodigiosin. Further, vanderwaals
energy value of prodiogiosin was seven-fold lower com-
pared to cycloprodigiosin. Such lower vanderwaals energy
value denoted the impact of hydrogen bonding property
of these compounds during protein/enzyme interaction.
Structure-functional relationship of prodigiosin and
cycloprodigiosin was evaluated to know their biological
activity against the COX-2 using the 3D structure of the
receptor retrieved from protein data bank site of COX-2
enzyme (pdb code: COX-2). For this the docked bindingTable 1 Energy values of prodigiosin and
cycloprodigiosin before and after energy minimization
Parameter Prodigiosin Cycloprodigiosin
Initial potential energy 57.223 150.369
Initial RMS gradient 22.477 43.156
Potential energy 27.531 40.730
Vanderwaals energy −7.284 −1.337
RMS gradient 0.107 0.0089mode was established to link the docking scoring func-
tion with these selected compounds and protein. Ana-
lysis of the binding pattern between COX-2 protein and
ligand suggested that the binding pattern also varied
with the ligand nature (Figure 2). This could be exem-
plified based on the observation that cyclprodigiosin
interacted with COX-2 protein amino acid residues of
Tyr324, Phe487 and Arg89 while prodigiosin interaction
was observed with only two amino acid residues i.e.,
with Leu321 and Tyr324. However, the interaction of
standard anticancer compound, rofecoxib, was noticed
with only one amino acid residue i.e., Arg89 of COX-2
protein, whereas other standard compound, celecoxib,
indicated binding pattern with five amino acid residues
(His58, tyr324, gln161, leu321 and Arg89) (Table 2). This
docking data with COX-2 protein active site amino acid
residues revealed that these two selected prodigiosin
and cycloprodigiosin interact with COX-2 protein other
than active site. This is because, it was well documented
in the literature that COX-2 active possess three import-
ant regions; a hydrophobic pocket characterized by the
presence of Tyr385, Trp387, Phe518, Ala201, Tyr248 and
Leu352. The second key region is associated with three
hydrophilic amino acid residues (Arg120, Glu524 and
Tyr355) which is located at the entrance of the active site
while third is a side pocket characterized with the pres-
ence of His90, Arg513 and Val523 (Priscilla et al. 2011).
The obtained docking data is in accordance with
reported data on synthetic compounds where amino
acid residues such as His90, Arg120, Gln192, Val349,
Leu352, Ser353, Tyr355, Leu359, Tyr385, Trp387, Arg513,
Ala516, Phe518, Val523, Gly526, Ala527, Leu531 associated
with A chain of COX-2 protein were involved for pro-
tein–ligand complementarily activity.
Critical evaluation of the nature of binding interaction
of these selective prodigiosin and cycloprodigiosin fur-
ther indicated that H-bonding with two amino acid resi-
due, Leu321 and Try324 of COX-2 protein is the only one
Figure 2 Binding pose of ligand molecules of selected (prodigiosin and cycloprodigiosin) and standard (cellecoxib and rofecoxib) with
different COX-2 protein (Docking of ligand into the binding pocket of inflammatory proteins establishing interactions with the active
site default colors).
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prodigiosin the binding is by three different interac-
tions; H-bonding with Tyr324, Pi-Pi interaction with
Phe487 and Pi-Cation nature of binding with amino acid
residue Arg89 of COX-2 protein (Table 2). This binding
pattern data further suggested that H-binding is com-
mon with both selected tripyrrole compounds i.e.
prodigiosin and cycloprodigiosin (Table 2). The ob-
served anti-inflammatory activity with rofecoxib and
celecoxib in association with interactive binding with
COX-2 protein further denote that the selectedTable 2 Type of interactions and interacting amino acid resid
COX-2 Protein H-Bonding V-wa
Cycloprodigiosin Tyr324 -----
Prodigiosin Leu321, Tyr324 -----
Rofecoxib ----- -----
Celecoxib His58, tyr324, gln161, leu321 -----prodigiosin and cycloprodigiosin could be effectively
used as anti- inflammatory agents. This could be con-
firmed based on the fact that both referral compounds
(rofecoxib and celecoxib) showed Pi-cation interaction
with COX-2 protein at Arg89 (Table 2). In addition, H-
bonding also observed in case of celecoxib with four dif-
ferent amino acid residues (His58, Tyr324, Gln161 and
Leu321) of COX-2 protein. It is interesting to note that
prodigiosin, cycloprodigiosin and celecoxib have com-
mon binding site at Tyr324 of COX-2 protein. Further,
celecoxib also observed to reveal interaction with COX-2ues of COX-2 protein with selected ligands





Table 3 Fitness score values as well as hydrogen bonding
interaction values between COX-2 protein and ligand
molecules
COX-2 protein Fitness S(hb_ext) S(vdw_ext) S(hb_int) S(int)
Prodigiosin 59.62 1.95 48.88 0.00 −9.54
Cycloprodigiosin 37.61 1.62 37.42 0.00 −15.46
Rofecoxib 44.59 0.00 33.65 0.00 −1.69
Celecoxib 62.15 2.18 46.59 0.00 −4.09
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prodigiosin with Leu321 and cycloprodigiosin Pi-cation
interaction with Arg89 residue. This observation further
confirm that selected prodigiosin and cycloprodigiosin
may be an effective anti-inflammatory compounds espe-
cially with respect to COX-2 protein mediated inflam-
mation however, differ in bonding pattern with protein
(Dilber et al. 2008; Llorens et al. 2002). This could be
also evidenced from the energy minimized 3D struc-
tures of prodigiosin and cycloprodigiosin (Figure 1).
This data is contradictory with literature reports where
docking of the synthetic compounds depicted three dif-
ferent types of binding patterns in general. Use of se-
lective COX-2 inhibitors such as SC-558, the bonding
was in the close vicinity of the hydrophobic pocket and
the phenylsulphonamide group occupied the side
pocket and showed binding with His90 and an inter-
action with Arg513 which has also been identified as an
important residue in the binding of selective COX-2 in-
hibitors according to the site- directed mutagenesis data
(Kurumbail et al. 1996). However, in another study,
docking of Diclofenac revealed that its orientation
makes the residues of side pocket thereby the hydro-
philic pocket of COX-2 protein is inaccessible and the
phenyl acetic acid moiety is orientated towards Tyr385
and Ser530 and hence possess H-bonding interaction
(Dilber et al. 2008). Ibuprofen and Naproxen when
docked into the active site of the COX-2 enzyme, the
interacting residues 120 were observed to be Arg120 and
Tyr355 (Llorens et al. 2002). This comparative analysis
of literature data and present investigation further indi-
cated that the prodigiosin and cycloprodigiosin influ-
ence the active site confirmation of COX-2 protein by
interacting at different place other than active site and
induces the anti-inflammatory function.
In view of the above, fitness score values were mea-
sured using Swiss PDB viewer considering steric and
electrostatic properties. The data revealed binding pat-
tern differ with the 3D topology of the prodigiosin to
cycloprodigiosin and influence fitness score value.
Higher fitness score of 59 was noticed with prodigiosin
while only fitness score of 37 was observed for
cycloprodigiosin (Table 3) suggesting that more inter-
action of prodigiosin with COX-2 enzyme. This isinteresting because, though higher fitness score was no-
ticed for prodigiosin, its interaction with COX-2 protein
was only with two amino acid (Leu321 and Tyr324) resi-
dues (Table 2) while, cycloprodiogiosin however,
showed interaction with three amino acid (Tyr324,
Phe487 and Arg89) residues (Table 2). Further analysis of
external hydrogen binding pattern between enzyme and
selected tripyrrole compounds denoted 1.95 and 1.62
for prodigiosin and cycloprodigiosin, respectively. How-
ever, interaction between enzyme and compounds was
not observed at internal hydrogen bonding level
(Table 3). In addition, evaluation of vanderwalls inter-
action denoted more than 20% higher bonding with
prodigiosin to that cycloprodigiosin (Table 3). The
Table 1 also indicated the static interaction relationship
between COX-2 and selected tripyrrole compounds.
The observed negative interaction values do indicate a
better steric interaction. It is evident that more steric
interaction was noticed with cycloprodigiosin compared
to prodigiosin. Based on docking, prodigiosin could be a
potential anti-inflammatory agent against COX-2 asso-
ciated inflammation reactions.Conclusions
The development of novel compounds with biological ac-
tivity is an urgent need. In the present study the COX-2
protein was successfully docked onto the both prodigiosin
and cycloprodigiosin for drug interaction study to have a
track in the ongoing race between drug development and
new drugs especially new compounds which are more im-
portant for the discovery of new hits using molecular
methods. The Fitness scores of prodigiosin and cyclo-
prodigiosin were calculated using the GOLD software.
Though the binding pattern of ligands with COX-2 dif-
fered respect to H-bonding, Pi- interaction and Pi-cation
of prodigiosin and cycloprodigiosin, fitness score values
substantiate the hypothesis that prodigiosin has the poten-
tial to inhibit the COX-2 protein.
Hence, it is concluded that that prodigiosin could be a
potent antinflamatory target molecule against COX-2
which may be worth for further clinical trails.
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